- Trial phase
- Approved
- Time to market
- Already marketed since 2013 (US) and 2014 (EU).
- Why 3/10
- No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for NovoEight in the next 12 months. It is an already-approved, marketed drug with no pending regulatory decision. NovoEight is also a very small part of Novo Nordisk's massive pipeline, where the entire rare disease segment accounts for roughly 6% of sales.
No upcoming binary catalysts exist for NovoEight. Investors should watch for any biosimilar entry following patent expirations, and monitor Novo Nordisk's quarterly rare disease segment sales for trends. The drug's commercial trajectory is a rounding error for NVO's overall thesis, which is dominated by semaglutide (Ozempic/Wegovy) dynamics.
Price Chart
Executive Summary
NovoEight (turoctocog alfa) is a recombinant factor VIII replacement therapy for hemophilia A, approved by the FDA in 2013 and marketed by Novo Nordisk. It is a mature, standard half-life product in a competitive market that includes Novo Nordisk's own extended half-life successor Esperoct, as well as products from Takeda, Bayer, Pfizer and others. For Novo Nordisk (NVO), a $180B+ market cap company driven overwhelmingly by its obesity and diabetes franchises, NovoEight is a negligible revenue contributor within the ~6% rare disease segment. There are no pending regulatory catalysts for this drug, and patent expirations around 2025 may open the door to biosimilar competition.
How It Works
NovoEight is a lab-made version of clotting factor VIII, a protein that people with hemophilia A lack or have too little of. By injecting it intravenously, the drug temporarily restores the blood's ability to clot normally, preventing or stopping bleeding episodes.
Trial Status
FDA-approved since October 2013 for adults and children with hemophilia A. The pivotal guardian clinical trial program (Phase 3) demonstrated safety and efficacy for on-demand bleeding control, perioperative management, and routine prophylaxis. Post-marketing studies (guardian 2 extension, guardian 5 real-world) have continued to track long-term safety.
The Two-Sided Case
Upcoming Catalysts
- No upcoming regulatory catalysts for NovoEight specifically. Patent expirations (reportedly around 2025) could eventually enable biosimilar competition, but no biosimilar applications are publicly known.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVO NORDISK A S 6-K NVO ·Originating report